PMID- 36935858
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230321
IS  - 2405-6308 (Electronic)
IS  - 2405-6308 (Linking)
VI  - 39
DP  - 2023 Mar
TI  - Early complete tumor response as a survival predictor in hepatocellular carcinoma 
      patients receiving stereotactic body radiation therapy.
PG  - 100465
LID - 10.1016/j.ctro.2022.03.010 [doi]
LID - 100465
AB  - BACKGROUND AND PURPOSE: To evaluate the different response patterns after 
      Stereotactic Body Radiation Therapy (SBRT) and their predictive value in local 
      control and progression of hepatocellular carcinoma (HCC). MATERIALS AND METHODS: 
      Seventy-two HCC patients who were treated with SBRT during 2015-2020 were 
      included in this retrospective study. The assessment was made using MRI, CT, and 
      PET-CT. Local and systemic responses were determined according to modified 
      Response Evaluation Criteria in Solid Tumors (mRECIST) criteria during follow up. 
      Patients were categorized as early responders (complete response during 6 months 
      after radiotherapy) or non-early responders (the rest of the patients). 
      Prognostic factors were determined using multivariate logistic models. RESULTS: 
      The median follow-up was 24.0 months (range, 7.7-74.5 months). We found that 
      84.7%（61/72) of patients achieved a complete response. Early responses occurred 
      in 45 patients (45/72, 62.5%), and they had 1-, 2-, and 5- year intrahepatic 
      outfield-free survival (OutFFS) rates of 86.2%, 80.3%, and 76.3% vs. 55.3%, 
      44.7%, and 33.5% in non-early responses patients, whereas the 1-, 2-, and 5- year 
      distant metastasis-free survival (DMFS) were 95.5%, 84.5% and 79.5% and 74.1%, 
      56.2% and 56.2%, respectively. The 1-, 2-, and 5-year overall survival (OS) were 
      97.7%, 92.1%, 79.1%, and 85.2%, 53.8%, and 40.3%, respectively. Multivariate 
      analysis revealed that early tumor response was an independent predictor of 
      OutFFS, DMFS, and OS. CONCLUSIONS: Early complete tumor response within 6 months 
      after radiotherapy predicted better intrahepatic outfield-free survival, distant 
      metastasis-free survival, and overall survival outcomes. Confirmation is 
      warranted for early response on SBRT to guide decision making.
CI  - (c) 2022 The Authors.
FAU - Wu, Qi-Qiao
AU  - Wu QQ
AD  - Department of Radiation Oncology, Fudan University Zhongshan Hospital, Xiamen 
      Branch, Jinhu Road 668, Xiamen 361006, China.
FAU - Chen, Yi-Xing
AU  - Chen YX
AD  - Department of Radiation Oncology, Fudan University Zhongshan Hospital, Fenglin 
      Road 188, Shanghai 200030, China.
FAU - Du, Shi-Suo
AU  - Du SS
AD  - Department of Radiation Oncology, Fudan University Zhongshan Hospital, Fenglin 
      Road 188, Shanghai 200030, China.
FAU - Hu, Yong
AU  - Hu Y
AD  - Department of Radiation Oncology, Fudan University Zhongshan Hospital, Fenglin 
      Road 188, Shanghai 200030, China.
FAU - Yang, Ping
AU  - Yang P
AD  - Department of Radiation Oncology, Fudan University Zhongshan Hospital, Fenglin 
      Road 188, Shanghai 200030, China.
FAU - Zeng, Zhao-Chong
AU  - Zeng ZC
AD  - Department of Radiation Oncology, Fudan University Zhongshan Hospital, Fenglin 
      Road 188, Shanghai 200030, China.
LA  - eng
PT  - Journal Article
DEP - 20220808
PL  - Ireland
TA  - Clin Transl Radiat Oncol
JT  - Clinical and translational radiation oncology
JID - 101713416
PMC - PMC10014333
OTO - NOTNLM
OT  - Complete response
OT  - Helical intensity-modulated radiotherapy
OT  - Hepatocellular carcinoma
OT  - Liver
OT  - Stereotactic body radiotherapy
COIS- The authors declare that they have no known competing financial interests or 
      personal relationships that could have appeared to influence the work reported in 
      this paper.
EDAT- 2023/03/21 06:00
MHDA- 2023/03/21 06:01
PMCR- 2022/08/08
CRDT- 2023/03/20 03:36
PHST- 2021/09/01 00:00 [received]
PHST- 2022/02/21 00:00 [revised]
PHST- 2022/03/24 00:00 [accepted]
PHST- 2023/03/20 03:36 [entrez]
PHST- 2023/03/21 06:00 [pubmed]
PHST- 2023/03/21 06:01 [medline]
PHST- 2022/08/08 00:00 [pmc-release]
AID - S2405-6308(22)00023-4 [pii]
AID - 100465 [pii]
AID - 10.1016/j.ctro.2022.03.010 [doi]
PST - epublish
SO  - Clin Transl Radiat Oncol. 2022 Aug 8;39:100465. doi: 10.1016/j.ctro.2022.03.010. 
      eCollection 2023 Mar.